OpGen, Inc.Announces $ 25 Million Recorded Direct Offer at Market Price Under NASDAQ Rules

GAITHERSBURG, Maryland, February 9, 2021 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to fight infectious disease, today announced it has entered into a definitive agreement with a single U.S. institutional investor focused on healthcare to purchase of (i) 2,784,184 ordinary shares (ii) 5,549,149 pre-funded warrants (the “pre-funded warrants”), each pre-funded warrants exercisable for one common share. The Company has also agreed to issue to the investor, as part of a concurrent private placement, unregistered common share purchase warrants (the “common warrants”) to purchase 4,166,666 common shares of the society. Each common share and the accompanying common warrant are sold together at a combined offering price of $ 3.00, and each pre-funded warrant and accompanying common warrant are sold together at a Combined offer price of $ 2.99, in accordance with a registered direct offer, at market price under Nasdaq rules. The pre-funded warrants are immediately exercisable, at an exercise price of $ 0.01, and may be exercised at any time until all pre-funded warrants are fully exercised. The ordinary warrants will have an exercise price of $ 3.55 per share, be exercisable from the sixth anniversary of the date of issue and will expire five and a half (5.5) years from the date of issue. ‘issue (collectively, the “Offer”).

The placement is expected to close on or around February 11, 2021, subject to the satisfaction of customary closing conditions.

AGP / Alliance Global Partners is acting as sole placement agent for the Offer.

This offering was made pursuant to a current registration statement on Form S-3 (File No. 333-236106) previously filed and declared effective by the United States Securities and Exchange Commission (the “SEC”). This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal. prior to registration or qualification under the securities laws of any such state or jurisdiction. A prospectus supplement relating to the Common Shares sold under the Offer will be filed by OpGen with the SEC. When available, copies of the Prospectus Supplement, along with accompanying prospectuses, may be obtained from the SEC’s website at www.sec.gov or from AGP / Alliance Global Partners. , 590 Madison Avenue, 28th Floor, New York, New York 10022 or by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities hereunder, and there will be no sale of such securities in any jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification. under the securities laws of such jurisdiction.

ABOUT OPGEN, INC.

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to fight infectious disease. Together with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we develop and market molecular microbiology solutions that help guide clinicians with faster, actionable information on life-threatening infections to improve patient outcomes and reduce the spread infections caused by multidrug-resistant microorganisms. , or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, as well as the ARES technology platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for prediction of response to antibiotics.

For more information, please visit www.opgen.com.

OPGEN FORWARD-LOOKING STATEMENTS:

This press release contains forward-looking statements regarding the Offer. These statements and other statements regarding OpGen’s future plans and objectives constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended for benefit from the safe harbor of responsibility established by the Private Securities Litigation Reform Act of 1995. For example, the expected closing date of the Offer is a forward-looking statement. Such statements are subject to risks and uncertainties which are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, without limitation, our use of proceeds of the Offer and that we may not use such product effectively, our ability to develop successfully, by in a timely and cost effective manner, seek and obtain regulatory clearance for and market our product and service offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the achievement of expected benefits of our business combination transaction with Curetis GmbH, the success of our marketing efforts, the impact of COVID-19 on the operations, financial results and marketing efforts of the Company as well as on the capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic factors and competitive. For a discussion of the most important risks and uncertainties associated with OpGen’s business, please see our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We assume no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen contact:
Olivier Schacht
CEO
[email protected]

Press contact:
Matthew Bretzius
Marketing and public relations FischTank
[email protected]

Investor contact:
Megan Paul
Edison Group
[email protected]


Source link

About Ariella McGuire

Check Also

Mid-market loan issuance stabilizes in 2Q, strong 2S expected

Through Leela Parker Deo, Loan Pricing Company NEW YORK, July 11 (LPC) – Syndicated loan …

Leave a Reply

Your email address will not be published. Required fields are marked *